Submit your email to push it up the queue
Novartis Pharmaceuticals UK Limited, a prominent player in the global healthcare landscape, is headquartered in Great Britain. Established in 1996, the company has made significant strides in the pharmaceutical industry, focusing on innovative medicines and advanced therapies across various therapeutic areas, including oncology, cardiology, and immunology. With a commitment to research and development, Novartis is renowned for its unique portfolio of prescription medications and cutting-edge treatments that address unmet medical needs. The company has achieved notable milestones, including the launch of groundbreaking therapies that have transformed patient care. As a leader in the pharmaceutical sector, Novartis Pharmaceuticals UK Limited continues to enhance its market position through strategic partnerships and a robust pipeline of products, solidifying its reputation for excellence in healthcare innovation.
How does Novartis Pharmaceuticals UK Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Novartis Pharmaceuticals UK Limited's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novartis Pharmaceuticals UK Limited, headquartered in Great Britain, currently does not report specific carbon emissions data for the most recent year. The company is a current subsidiary of Novartis AG, which cascades its climate commitments and emissions data down to its subsidiaries. As part of its climate strategy, Novartis AG has set various reduction targets and initiatives that influence Novartis Pharmaceuticals UK Limited. These include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are aimed at reducing greenhouse gas emissions across their operations. However, specific reduction targets for Novartis Pharmaceuticals UK Limited have not been detailed. The absence of direct emissions data highlights the importance of Novartis AG's overarching climate commitments, which guide the environmental strategies of its subsidiaries. As the company continues to align with global climate goals, it remains focused on sustainability and reducing its carbon footprint in the pharmaceutical industry.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis Pharmaceuticals UK Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.